USV interferon alfa-2b
Interferon alfa-2b biosimilar developed by Not stated in the CDSCO list. Reference product Intron A and PegIntron (Merck).
Brands by market: Brand not published by CDSCO (India, import) · Commercial partner or holder: USV (import)
FDANot listed
EMANot listed
MHRANot listed
PMDANot listed
HCNot listed
CDSCOSep 2009permitted
EDENot listed
Approved or registered in 1 of 7 markets
Connections
About USV interferon alfa-2b
USV has held an Indian import permission for interferon alfa-2b since September 2009, for chronic hepatitis B and C. The manufacturer is not named in the published list.
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union
Not listed by EMA.
MHRA
United Kingdom
Not listed by MHRA.
PMDA
Japan
Not listed by PMDA.
HC
Canada
Not listed by HC.
CDSCO
India
Central Drugs Standard Control OrganisationApprovedBrand
Not published by CDSCO (INN only)
Holder or applicant
USV Ltd
Pathway
Import and marketing permission
Approved
Sep 2009
Application or permission
Import permission
Indications as licensed
Chronic hepatitis B and C
Presentations
3 and 5 million IU lyophilised vials
Source
S013 (CDSCO) · checked Sep 2026
EDE
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where USV interferon alfa-2b holds an approval, these are the other interferon alfa-2b biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| CDSCO | 2 | Intas Pharmaceuticals (Intas peginterferon alfa-2b), Zydus Lifesciences (Zydus peginterferon alfa-2b) |
Chronology
- CDSCOSep 2009CDSCO permission granted
Sources
S013CDSCO, import and market permissions till 2019 (r-DNA) Primary (regulator)
Planning interferon alfa-2b biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.